Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among…

In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is…

Experienced global leader Takafumi Horii explains the rationale behind returning to his home nation of Japan to head up Takeda’s Japan Oncology…

Cancer is one of the most frightening words in any language but is especially heart-wrenching when it comes to children. João de Bragança, President…

While the overall Japanese pharma market is expected to remain at a similar overall value up to 2023, the oncology segment is expected to grow by five…

Professor Ashok Venkitaraman introduces his work in Singapore, coordinating and catalysing research on the causes of cancer in Asia, and translating…

Jasper Kunow, MSD’s managing director for Central Eastern Europe, outlines the threat that cancer still poses to Europe, the challenges of enacting…

Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer…

Kenneth Tan has been President for Asia Pacific & Japan at cancer-focused medical device player Varian since February 2019. In a recent…

The EFPIA’s Nathalie Moll outlines the significance of Europe’s Beating Cancer Plan to cancer patients in Europe, and its potential to boost the…

[caption id="attachment_92156" align="alignleft" width="227"] Photo: Sofia Linden / Oslo Cancer Cluster[/caption] Oncologist Jon Amund Kyte shares…

Norway, more well-known internationally as an innovation hub for oil & gas and marine biology, is attempting to reverse the trend of reducing…